Author:
Collins Sean E.,Grant Philip M.,Richardson Eugene T.,Zolopa Andrew R.
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on Integrase Inhibitor Use in Antiretroviral Treatment-Naive HIV-Infected Individuals from the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf . Accessed November 8, 2013. This DHHS website maintains updated treatment recommendations for the care of HIV-infected patients.
2. Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77–85. This study showed durable efficacy of raltegravir based therapy over long-term follow-up. After 5 years, raltegravir + TDF/FTC was superior to EFV/TDF/FTC. Raltegravir’s superiority was driven by better tolerability and less drug discontinuation.
3. Fesen MR, Kohn KW, Leteurtre F, Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A. 1993;90(6):2399–403.
4. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287(5453):646–50.
5. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012;13 Suppl 2:1–85.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献